Opinion: $2 Million Gene Therapy Cures Need New Financing Models

Gene therapy breakthroughs offer curative treatments for previously incurable diseases, but their extraordinary costs—some exceeding $2 million per patient—create a critical barrier to patient access. Medical expert William Padula argues that the challenge is not the lack of innovative cures, but rather the absence of adequate infrastructure and financing mechanisms to deliver these treatments to those who need them. As gene therapies for conditions like certain cancers, genetic disorders, and inherited diseases continue to emerge from clinical research, healthcare systems must develop sustainable payment models. Without innovative financing solutions, only wealthy patients will benefit from these revolutionary treatments, widening healthcare disparities. Policymakers, insurers, and pharmaceutical companies must collaborate to create equitable access frameworks that make curative gene therapies available to all patients, regardless of economic status.